Vericel Corporation (VCEL)
NASDAQ: VCEL · Real-Time Price · USD
38.29
+0.83 (2.22%)
At close: Jun 15, 2026, 4:00 PM EDT
38.98
+0.69 (1.80%)
After-hours: Jun 15, 2026, 4:30 PM EDT
Vericel Revenue
Vericel had revenue of $68.43M in the quarter ending March 31, 2026, with 30.09% growth. This brings the company's revenue in the last twelve months to $292.09M, up 22.45% year-over-year. In the year 2025, Vericel had annual revenue of $276.26M with 16.45% growth.
Revenue (ttm)
$292.09M
Revenue Growth
+22.45%
P/S Ratio
6.69
Revenue / Employee
$733,884
Employees
398
Market Cap
1.96B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 276.26M | 39.04M | 16.45% |
| Dec 31, 2024 | 237.22M | 39.71M | 20.10% |
| Dec 31, 2023 | 197.52M | 33.15M | 20.17% |
| Dec 31, 2022 | 164.37M | 8.18M | 5.24% |
| Dec 31, 2021 | 156.18M | 32.01M | 25.77% |
| Dec 31, 2020 | 124.18M | 6.33M | 5.37% |
| Dec 31, 2019 | 117.85M | 26.99M | 29.71% |
| Dec 31, 2018 | 90.86M | 26.93M | 42.13% |
| Dec 31, 2017 | 63.92M | 9.54M | 17.54% |
| Dec 31, 2016 | 54.38M | 3.22M | 6.28% |
| Dec 31, 2015 | 51.17M | 22.37M | 77.69% |
| Dec 31, 2014 | 28.80M | 28.78M | 151,457.89% |
| Dec 31, 2013 | 19.00K | -2.00K | -9.52% |
| Dec 31, 2012 | 21.00K | 3.00K | 16.67% |
| Dec 31, 2011 | 18.00K | -71.00K | -79.78% |
| Jun 30, 2010 | 89.00K | -93.00K | -51.10% |
| Jun 30, 2009 | 182.00K | -340.00K | -65.13% |
| Jun 30, 2008 | 522.00K | -163.00K | -23.80% |
| Jun 30, 2007 | 685.00K | -178.00K | -20.63% |
| Jun 30, 2006 | 863.00K | -46.00K | -5.06% |
| Jun 30, 2005 | 909.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lakefront Biotherapeutics NV | 1.20B |
| Harmony Biosciences Holdings | 899.11M |
| ADMA Biologics | 509.86M |
| Zai Lab | 453.28M |
| Iovance Biotherapeutics | 285.61M |
| Nektar Therapeutics | 55.63M |
| Ocular Therapeutix | 52.04M |
| Stoke Therapeutics | 32.08M |
VCEL News
- 6 days ago - Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026 - GlobeNewsWire
- 5 weeks ago - Vericel price target raised to $70 from $64 at H.C. Wainwright - TheFly
- 5 weeks ago - Vericel reports Q1 EPS (12c), consensus (16c) - TheFly
- 5 weeks ago - Vericel raises FY26 revenue guidance to $326M-$336M from $316M-$326M - TheFly
- 5 weeks ago - Vericel Earnings Call Transcript: Q1 2026 - Transcripts
- 5 weeks ago - Vericel Earnings release: Q1 2026 - Filings
- 5 weeks ago - Vericel Slides: Q1 2026 - Filings
- 5 weeks ago - Vericel Quarterly report: Q1 2026 - Filings